Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Stella

Home/Cytomegalovirus Infections/

View on ClinicalTrials.gov

Recruiting

Back to Cytomegalovirus Infections trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts

Key details

Phase

Post-approval study

Sponsor

Tufts Medical Center

Enrollment target

~25 participants

Started

February 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.